Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00243685 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
A Phase 2 study, sponsored by Pierian Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00243685 is a Phase 2 study that has completed, run by Pierian Biosciences. The registered enrollment target is 150 participants.
The verdict
NCT00243685, a Phase 2 study, has completed, sponsored by Pierian Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
DiaTech is a private company performing patient specific cancer chemosensitivity testing for patients and physicians. DiaTech Oncology is doing this clinical study to see if an experimental new technology called the microculture kinetic (MiCK) assay will predict treatment outcome and can help to direct the chemotherapy of cancer subjects. This study is focused on subjects diagnosed with breast, ovarian, lung, and colon malignancies and low-grade lymphomas. Study Objectives: * To evaluate the ability of the MiCK assay to predict the outcome of chemotherapy of cancer patients. * To evaluate the ability of the MiCK assay to guide chemotherapy of cancer patients.
Interventions
- OTHER Laboratory Assay
- OTHER Mick Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00243685
The ClinicalTrials.gov registry entry for NCT00243685 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pierian Biosciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Assay is the first listed.
NCT00243685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00243685 about?
NCT00243685 is a clinical study titled "Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis". DiaTech is a private company performing patient specific cancer chemosensitivity testing for patients and physicians. DiaTech Oncology is doing this clinical study to see if an experimental new technology called the microculture kinetic (MiCK) assay will predict treatment outcome and can help to dir...
What is the current status of trial NCT00243685?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2006-09. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00243685?
The interventions under investigation include: Laboratory Assay (OTHER), Mick Assay (OTHER).
Who is sponsoring clinical trial NCT00243685?
This trial is sponsored by Pierian Biosciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.